Revolution Medicines priced concurrent offerings raising ~$2.0 billion:
10,563,381 shares of common stock at $142.00 per share (~$1.5B gross) and $500M of 0.50% convertible senior notes due 2033.4
Net proceeds estimated at ~$1,435M from stock and ~$486.8M from notes, for general corporate purposes including R&D and commercialization.4
Positive phase 3 data for daraxonrasib (pan-RAS inhibitor) in metastatic pancreatic ductal adenocarcinoma:
median OS 13.2 months vs. 6.7 months for chemotherapy, hitting OS and PFS endpoints.6
Trial in previously treated patients with RAS mutations; drug well-tolerated, results to support regulatory submissions and ASCO 2026 presentation.6
Offering upsized from initial $750M common stock; settlements April 16-17, 2026; company eyes pivotal trial readout in H1 2026 and global expansion.34
Sources:
3. https://app.dealroom.co/news/feed/revolution-medicines-reports-2b-cash-position-eyes-pivotal-pancreatic-cancer-trial-readout-in-h1-2026
4. https://www.stocktitan.net/news/RVMD/revolution-medicines-inc-prices-2-0-billion-in-concurrent-upsized-w30g5dngxpii.html
6. https://www.fiercebiotech.com/biotech/revolutions-much-hyped-ras-inhibitor-hits-key-survival-goals-phase-3-pancreatic-cancer